Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma
NCT03278782Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2017
- Primary completion
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in peripheral T-cell lymphoma (PTCL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety of Pembrolizumab in Combination With Romidepsin. Started Nov 2017; status: completed.
02
Drugs
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03278782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03278782.